Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline
Therapeutics Inc. (“Stemline” or the “Company”) (NASDAQ:STML) into potential breaches of fiduciary duty by the Company’s Board of
Directors (the “Board”).
Stemline, headquartered in New York, NY, is a clinical-stage biopharmaceutical company focused on the development and
commercialization of oncology therapies. Newman Ferrara’s investigation focuses on decisions made by the Board, without shareholder
approval, the result of which significantly diminish shareholder value and do not benefit the Company. Considering the Company’s
lackluster performance since its February 2013 IPO, it is clear that the Board lacks the ability to fairly assess and oversee the
Company’s direction and leadership.
Current Stemline stockholders seeking more information on this matter are invited to contact Newman Ferrara attorneys Jeffrey
Norton (jnorton@nfllp.com) or Ryan Jerome (rjerome@nfllp.com) to discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New York City with attorneys specializing in complex commercial and
multi-party litigation, securities fraud and shareholder litigation, consumer protection, civil rights, and real estate. For more
information, please visit the firm website at www.nfllp.com.
Newman Ferrara LLP
Jeffrey M. Norton, 212-619-5400
jnorton@nfllp.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180108006716/en/